Could a diabetes drug ease a rare heart condition?
NCT ID NCT06433050
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether sotagliflozin, a drug already used for heart failure, can help people with a type of hypertrophic cardiomyopathy that doesn't block blood flow. Twenty-six adults will take the drug or a placebo for 12 weeks, then switch, to see if it improves exercise capacity and heart function. The goal is to find a new treatment option for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sotagliflozin (a drug that blocks two sodium-glucose transporters, used for heart failure and diabetes)
What this could lead to
If it works, this could point toward a new treatment option for people with nonobstructive hypertrophic cardiomyopathy, potentially improving their exercise ability and heart function.
What could go wrong
This is a very early, small trial with only 26 participants, so results may not apply to everyone. The drug may not show clear benefits or could cause side effects like dehydration or urinary tract infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY WITHOUT OBSTRUCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••